Single-Nucleus RNA Sequencing Exposes Mixed Lineage Programs in Wilms Tumor Blastema
Wilms tumor has long been viewed through the lens of kidney development, but this study shows how unstable that developmental program can become once the tumor forms. Using single-nucleus RNA sequencing on treatment-naive, favorable-histology tumors, investigators mapped transcriptional activity across blastemal, stromal, and epithelial compartments against a reference atlas built from tumor-adjacent kidney and fetal kidney tissue. The result was not a tidy cancer map. It was a mosaic of renal lineage signals, fetal progenitor programs, and unexpected cross-lineage expression patterns that blur the boundary between normal nephrogenesis and malignant growth.
The dataset captured a core biological feature of favorable-histology Wilms tumor: its cells still behave as if they are trying, and failing, to complete developmental differentiation. Rather than forming a uniform malignant population, the blastema carried heterogeneous transcriptional states that aligned with the fetal nephron progenitor trajectory, especially the transition from “uninduced” to “early differentiating” cells. At the same time, other signatures associated with stromal identity appeared inside the blastemal compartment, showing that lineage restriction in this tumor is incomplete. A tumor can preserve developmental memory and still scramble the script.
Fetal Kidney Programs Persist, but They No Longer Stay in Their Lane
One of the clearest findings was the expression of PAX2 and PAX8 in tumor stroma. In normal fetal kidney development, these markers are largely confined to nephron lineage cells. Their presence in stromal compartments suggests lineage plasticity rather than strict cell identity, and in a pediatric renal tumor that plasticity is biologically consequential. It implies that cells within the microenvironment are not merely supportive scaffolding; they may participate in the same developmental rerouting that sustains the tumor.
The reverse phenomenon also appeared. The stromal marker POSTN was identified in tumor blastema, indicating that blastemal cells were not limited to canonical nephron progenitor signatures. They were simultaneously carrying stromal-associated features, a pattern that reinforces the idea that Wilms tumor cells occupy an unstable developmental state. In practical terms, this matters because histology alone cannot fully capture the molecular identity of the cells driving the tumor.
The study’s use of a fetal kidney reference atlas strengthened the interpretation of these findings. By comparing tumor nuclei to both adjacent kidney and fetal kidney, the analysis could separate normal developmental states from tumor-specific transcriptional drift. That approach showed that favorable-histology Wilms tumor is not simply a frozen snapshot of the fetal kidney. It is a distorted version of renal development in which blastemal, stromal, and epithelial identities overlap, reappear, or shift depending on the sample.
The Blastema Retains Developmental Signatures and Gains New Ones
The blastemal compartment preserved a number of pathways normally active in fetal nephron progenitors, including regulation of stem cell maintenance and axonogenesis. Those findings are important because they point to a tumor cell population that is not only proliferative but biologically poised for persistence. Stem cell maintenance pathways can help explain why the blastema remains undifferentiated, while axonogenesis-related programs may reflect broader developmental circuitry that has been redeployed in a malignant context.
At the same time, the blastema did not behave uniformly across all tumor samples. Some pathways were enriched only in specific tumors, indicating intertumoral variability layered on top of the shared fetal-like program. That heterogeneity is clinically meaningful. It suggests that two tumors with the same favorable histology may still rely on distinct molecular drivers, which could influence how they respond to therapy or which signaling nodes might be most vulnerable to intervention.
This is where single-nucleus RNA sequencing adds value beyond bulk profiling. Bulk RNA measures can flatten cell-to-cell diversity into an averaged signal, masking rare populations and mixed states. Here, the technique revealed both a common developmental backbone and sample-specific transcriptional differences. The tumor is not one transcriptome; it is many transcriptomes occupying the same mass.
Why Mixed Identity Matters at the Bedside
For pediatric oncology, the central question is not whether Wilms tumor resembles kidney development. It does. The more useful question is which developmental states are being preserved, distorted, or co-opted, and whether those states create exploitable therapeutic dependencies. The shared transcriptional features seen in the blastema suggest that some core pathways are conserved across tumors, while the tumor-restricted enrichments point to distinct signaling circuits that may not be visible on routine pathology.
This molecular heterogeneity could help explain why favorable-histology Wilms tumor remains biologically variable despite a shared diagnostic category. Histology captures architecture and cell appearance, but it does not resolve how the tumor’s cells are distributed across developmental states. By identifying both unifying signatures and divergent targets, snRNA-seq provides a framework for more granular classification of the disease. It also raises the possibility that future risk stratification may depend not only on histology and stage, but also on the dominant transcriptional programs inside the blastema.
A single tumor can contain renal progenitor logic, stromal leakage, and epithelial drift all at once.
The study does not claim that these transcriptional states immediately translate into new treatment choices, and it does not establish outcome associations. It does show that favorable-histology Wilms tumor is transcriptionally more complex than its name implies. The challenge now is to determine which of these lineage states are merely descriptive and which are biologically actionable, especially in the subset of tumors that preserve fetal nephron progenitor pathways while activating aberrant stromal features.
Molecular Targets May Depend on Which Cellular State Dominates
The most clinically relevant implication is that potential targets may vary by compartment and by sample. A pathway shared across blastemal tumors could support a broader therapeutic strategy, while tumor-specific enrichment may identify narrower vulnerabilities in selected patients. The same applies to the aberrant expression of stromal signatures inside blastema and nephron-lineage markers in stroma: these are not just curiosities. They are evidence that lineage plasticity is embedded in the tumor’s biology and may influence how malignant cells survive, differentiate, or resist treatment.
For now, the study offers a detailed transcriptional atlas rather than a direct therapeutic map. Its strength lies in showing how favorable-histology Wilms tumor can preserve fetal kidney programs while simultaneously violating them. That duality is the biological story: a pediatric renal cancer that still speaks the language of development, but with enough distortion to remain malignant. The remaining question is which of those developmental words will prove useful targets and which will remain markers of a tumor that has learned to mix cell identities in the same blastemal compartment.